Aids researchers seek go-ahead to test thalidomide: Drug trial planned on HIV-positive men
Steve Connor is the Science Editor of The Independent and i. He has won many awards for his journalism, including five-times winner of the prestigious British science writers’ award; the David Perlman Award of the American Geophysical Union; four times highly commended as specialist journalist of the year in the UK Press Awards; UK health journalist of the year and a special merit award of the European School of Oncology for his investigations into the tobacco industry. He has a degree in zoology from the University of Oxford and has a special interest in genetics and medical science, human evolution and origins, climate change and the environment.
Monday 26 July 1993
Doctors at St George's Hospital Medical School and the Chelsea and Westminster Hospital in London have applied for ethical approval to begin the drugs trial which they expect to start at the end of next month.
Professor Angus Dalgleish, an Aids researcher at St George's, said he had been applying to start a trial of thalidomide as an anti-Aids drug for 'the best part of a year'.
He said 40 patients had volunteered, the drug had been bought from a company in Brazil and the EC had agreed to fund the study. 'We're just waiting for final ethical approval,' he said.
'We're hoping to start as soon as possible, possibly the end of August. I think it should be OK because we've had our submission before (the ethical panel) several times now.'
Thalidomide, which was initially sold as a sedative and is now used to treat leprosy, is believed to 'damp down' a part of the immune system that Professor Dalgleish believes is responsible for helping to bring on Aids in people infected with HIV.
Researchers at the Rockefeller University in New York reported earlier this year that they believed thalidomide could alleviate the symptoms of Aids and slow or even halt its progress.
Professor Dalgleish believes that HIV causes the body's immune system to attack its own cells, similar to other so-called 'auto-immune' diseases. However, many other scientists disagree, which has frustrated Professor Dalgleish's attempts to begin a trial of thalidomide in the UK, he said.
Another problem has been the terrible notoriety of the drug itself. 'No drug company wants to have its name associated with it. We've had to buy it from a company in Brazil that is making it for leprosy treatment.'
He said the ethical protocol of the drugs trial made it 'absolutely mandatory' for all 40 volunteers to be men because of the risk of birth defects in women.
- 1 The difference between a migrant and refugee, in one sentence
- 2 Miley Cyrus calls out hypocrisy of women’s nipples being taboo
- 3 Celebrity Big Brother 2015: Tila Tequila kicked off show after 'describing Hitler as a good man'
- 4 iPhone 5c to be discontinued, no iPhone 6c to replace it
The difference between a migrant and refugee, in one sentence
Spain accused of 'provocation' after letting Russian submarine refuel off Gibraltar
Allonautilus scrobiculatus: World's 'rarest' creature spotted for only the third time ever
Miley Cyrus calls out hypocrisy of women’s nipples being taboo
Celebrity Big Brother 2015: Tila Tequila kicked off show after 'describing Hitler as a good man'
Climate change: 2015 will be the hottest year on record 'by a mile', experts say
Labour leadership: Jeremy Corbyn accused of 'deluding' young supporters with 'claptrap'
'Women only' train carriages: Jeremy Corbyn unveils radical move to tackle public harassment
Black holes are a passage to another universe, says Stephen Hawking
Iain Duncan Smith 'should resign over disability benefit death figures', says Jeremy Corbyn
Iain Duncan Smith calls for urgent ESA overhaul as part of drive to cut down welfare costs
£18000 - £30000 per annum: Recruitment Genius: A Sales Executive or Senior Sal...
£40000 - £55000 per annum: Recruitment Genius: This is an exciting opportunity...
£22000 per annum: Recruitment Genius: This industry leading company produces h...
£20000 - £40000 per annum: Recruitment Genius: This IT provider for the educat...